BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 18195681)

  • 1. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome.
    Minnema MC; van de Donk NW; Zweegman S; Hegenbart U; Schonland S; Raymakers R; Zijlmans JM; Kersten MJ; Bos GM; Lokhorst HM
    Bone Marrow Transplant; 2008 May; 41(9):779-84. PubMed ID: 18195681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple myeloma extramedullary relapse at the sellar and suprasellar region after autologous stem cell transplantation.
    De Jesus O
    Surg Neurol Int; 2024; 15():13. PubMed ID: 38344096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?
    Markovic U; Calafiore V; Martino E; Giubbolini R; Parisi MS; Romano A; Del Fabro V; Di Raimondo F; Conticello C
    Clin Case Rep; 2019 Sep; 7(9):1629-1636. PubMed ID: 31534716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease.
    Wang J; Shen N; Shen X; Zhang R; Jin Y; Li J; Chen L
    Ann Med; 2023; 55(2):2281657. PubMed ID: 38086395
    [No Abstract]   [Full Text] [Related]  

  • 5. A prognostic model for patients with primary extramedullary multiple myeloma.
    Zhang L; Chen S; Wang W; Wang Y; Liang Y
    Front Cell Dev Biol; 2022; 10():1021587. PubMed ID: 36506092
    [No Abstract]   [Full Text] [Related]  

  • 6. Central Nervous System Myeloma and Unusual Extramedullary Localizations: Real Life Practical Guidance.
    Sammartano V; Cerase A; Venanzi V; Mazzei MA; Vangone BE; Gentili F; Chiarotti I; Bocchia M; Gozzetti A
    Front Oncol; 2022; 12():934240. PubMed ID: 35875104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Impact of the Tumor Microenvironment on Multiple Myeloma Dissemination and Extramedullary Disease.
    Forster S; Radpour R
    Front Oncol; 2022; 12():941437. PubMed ID: 35847862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
    Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
    Front Immunol; 2021; 12():720571. PubMed ID: 34421924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary Lymphangitic Spread of Multiple Myeloma as Early Relapse after Autologous Stem Cell Transplantation.
    Thapa B; Ahmed G; Mohan M; Shponka V; Hari P
    Case Rep Hematol; 2021; 2021():5590975. PubMed ID: 33884207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms.
    Sewastianik T; Straubhaar JR; Zhao JJ; Samur MK; Adler K; Tanton HE; Shanmugam V; Nadeem O; Dennis PS; Pillai V; Wang J; Jiang M; Lin J; Huang Y; Brooks D; Bouxsein M; Dorfman DM; Pinkus GS; Robbiani DF; Ghobrial IM; Budnik B; Jarolim P; Munshi NC; Anderson KC; Carrasco RD
    Blood; 2021 Apr; 137(14):1905-1919. PubMed ID: 33751108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Factors for Postrelapse Survival after ex Vivo CD34
    Gomez-Arteaga A; Shah GL; Baser RE; Scordo M; Ruiz JD; Bryant A; Dahi PB; Ghosh A; Lahoud OB; Landau HJ; Landgren O; Shaffer BC; Smith EL; Koehne G; Perales MA; Giralt SA; Chung DJ
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2040-2046. PubMed ID: 32712326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.
    Montefusco V; Gay F; Spada S; De Paoli L; Di Raimondo F; Ribolla R; Musolino C; Patriarca F; Musto P; Galieni P; Ballanti S; Nozzoli C; Cascavilla N; Ben-Yehuda D; Nagler A; Hajek R; Offidani M; Liberati AM; Sonneveld P; Cavo M; Corradini P; Boccadoro M
    Haematologica; 2020 Jan; 105(1):193-200. PubMed ID: 31221778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma.
    Rasche L; Kortüm KM; Raab MS; Weinhold N
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30871078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysphagia as an Unusual Presentation of Myeloma.
    Raissi A; Chahbi Z; Zyani M; Darouassi Y
    Case Rep Hematol; 2018; 2018():6910624. PubMed ID: 30647981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From carcinoma through lymphoma to myeloma: a gastric mass diagnostic rollercoaster ride.
    Schmid MB; Kopfstein L
    BMJ Case Rep; 2018 Jul; 2018():. PubMed ID: 30065054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
    Garfall AL; Stadtmauer EA; Hwang WT; Lacey SF; Melenhorst JJ; Krevvata M; Carroll MP; Matsui WH; Wang Q; Dhodapkar MV; Dhodapkar K; Das R; Vogl DT; Weiss BM; Cohen AD; Mangan PA; Ayers EC; Nunez-Cruz S; Kulikovskaya I; Davis MM; Lamontagne A; Dengel K; Kerr ND; Young RM; Siegel DL; Levine BL; Milone MC; Maus MV; June CH
    JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses.
    de Haart SJ; Willems SM; Mutis T; Koudijs MJ; van Blokland MT; Lokhorst HM; de Weger RA; Minnema MC
    Blood Cancer J; 2016 May; 6(5):e426. PubMed ID: 27206246
    [No Abstract]   [Full Text] [Related]  

  • 18. Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma.
    Vincent L; Ceballos P; Plassot C; Méniane JC; Quittet P; Navarro R; Cyteval C; Szablewski V; Lu ZY; Kanouni T; Moreaux J; Cartron G; Klein B; Fegueux N
    Blood Cancer J; 2015 Aug; 5(8):e341. PubMed ID: 26295611
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma.
    Giaccone L; Brunello L; Festuccia M; Gilestro M; Maffini E; Ferrando F; Talamo E; Passera R; Boccadoro M; Omedè P; Bruno B
    Bone Marrow Transplant; 2015 Apr; 50(4):511-6. PubMed ID: 25665043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study.
    Zhang JJ; Sun WJ; Huang ZX; Chen SL; Zhong YP; Hu Y; An N; Shen M; Li X
    World J Surg Oncol; 2014 Jul; 12():234. PubMed ID: 25070574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.